SCHEDULE: Wasatch Advisors LP Discloses Stake in Esperion Therapeutics

Wasatch Advisors LP has filed a Schedule 13G, reporting beneficial ownership of 1,930,185 shares of Esperion Therapeutics Inc. common stock, representing 0.7% of the class.

Summary

• Wasatch Advisors LP has filed an amendment to its Schedule 13G filing.
• The filing indicates beneficial ownership of 1,930,185 shares of Esperion Therapeutics Inc. common stock.
• This ownership represents 0.7% of the total class of securities.
• Wasatch Advisors LP holds sole voting power and sole dispositive power for these shares.
• The filing is made under Rule 13d-1(b) of the Securities Exchange Act of 1934.
• The reporting entity, Wasatch Advisors LP, is organized in Delaware.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it is a routine disclosure of beneficial ownership by an investment advisor and does not contain operational or financial performance data.

Positives

• Wasatch Advisors LP has taken a position in Esperion Therapeutics Inc., suggesting a belief in the company's potential.
• The filing indicates a clear and sole beneficial ownership, simplifying the ownership structure.

Negatives

• The reported ownership stake of 0.7% is relatively small, suggesting a passive investment rather than a controlling interest.

Future Outlook

No specific future outlook or guidance is provided in this filing, as it pertains to ownership disclosure.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors accumulating positions. This filing indicates Wasatch Advisors LP's investment activity within the biopharmaceutical sector, specifically in Esperion Therapeutics Inc.

Stakeholder Impact

• Shareholders: The filing provides transparency regarding institutional ownership, which can be a factor in market perception.

Key Dates

Keywords

Esperion Therapeutics Inc., Wasatch Advisors LP, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Investment, Securities